168 related articles for article (PubMed ID: 16740435)
1. Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients.
Martínez-Mier G; Méndez-López MT; Estrada-Oros J; Budar-Fernandez LF; Soto-González JI; Méndez-Machado GF; Viñas Dozal JC
Arch Med Res; 2006 Jul; 37(5):635-8. PubMed ID: 16740435
[TBL] [Abstract][Full Text] [Related]
2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
3. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
4. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
Hanto DW; Chudzinski R
Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
[No Abstract] [Full Text] [Related]
5. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
7. Management of chronic allograft dysfunction by switch over to rapamycin.
Sundaram V; Abraham G; Fathima N; Sundaram V; Reddy YN; Mathew M; Sathiah V
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):37-42. PubMed ID: 20061690
[TBL] [Abstract][Full Text] [Related]
8. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
9. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
10. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
11. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
12. Long-term results after conversion from calcineurin inhibitors to sirolimus in renal transplant patients.
Martinez-Mier G; Avila-Pardo SF; Mendez-Lopez MT; Budar-Fernandez LF
Clin Transplant; 2010; 24(4):467-73. PubMed ID: 19744089
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years.
Engelen MA; Amler S; Welp H; Vahlhaus C; Gunia S; Sindermann JR; Rothenburger M; Stypmann J
Transplantation; 2011 May; 91(10):1159-65. PubMed ID: 21478817
[TBL] [Abstract][Full Text] [Related]
14. Conversion to sirolimus in kidney transplant recipients: a single-center study.
Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
[TBL] [Abstract][Full Text] [Related]
15. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus-based, calcineurin-inhibitor sparing immunotherapy, long-term (6-year) results.
Conti DJ; Petrov R; Elbalhoul O; Gallichio M
Transpl Immunol; 2008 Nov; 20(1-2):12-3. PubMed ID: 18793727
[TBL] [Abstract][Full Text] [Related]
17. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
[TBL] [Abstract][Full Text] [Related]
18. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
[TBL] [Abstract][Full Text] [Related]
19. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes.
Boratynska M; Banasik M; Patrzalek D; Klinger M
Exp Clin Transplant; 2008 Mar; 6(1):59-66. PubMed ID: 18405247
[TBL] [Abstract][Full Text] [Related]
20. New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients.
Sommerer C; Giese T; Meuer S; Zeier M
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1030-7. PubMed ID: 21060169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]